A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2001
11/29/2001	WO2000047104A9 Antagonists of hmg1 for treating inflammatory conditions
11/29/2001	WO2000045792A8 Hydrogel particle formulations
11/29/2001	WO2000041548A3 Methods for glucagon suppression
11/29/2001	WO2000041473A3 Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
11/29/2001	WO2000038666A3 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
11/29/2001	US20010047108 Method for making HBED
11/29/2001	US20010047105 EP4 receptor selective agonists in the treatment of osteoporosis
11/29/2001	US20010047035 Detecton, treatment and monitoring the patient with poor wound healing ability due to diabetes based on measurement of the breakdown product of nitric oxide (NO) in specimens taken from the patient under controlled conditions
11/29/2001	US20010047023 1-(p-(methylsulfonamido)phenyl)-3-trifluoromethyl-5-phenylpyra zolone and derivatives; antiinflammatory agents
11/29/2001	US20010047021 Tetrasubstituted benzimidazole carbamates
11/29/2001	US20010047007 Tyrosine kinase inhibitors
11/29/2001	US20010047000 E.g., ranolazine
11/29/2001	US20010046988 Especially treating fibromyalgia, chronic fatigue syndrome, psychogenic pain and chromic pain
11/29/2001	US20010046985 Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
11/29/2001	US20010046980 Method of treatment of prostate cancer
11/29/2001	US20010046962 Presynaptic neurotoxin such as botulinum toxin A
11/29/2001	US20010046959 Method of treating cancer with anti-neurotrophin agents
11/29/2001	US20010046958 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
11/29/2001	US20010046956 May contain another compound to treat diabetes, sexual dysfunction, atherosclerosis, insulin resistance, impaired glucose tolerance, hypercholesterolemia or hypertriglyceridemia
11/29/2001	US20010046526 Using plant extract from Musaceas family such as plantain or banana; treating athlete's foot, tinea cruris, tinea corpora, candidiasis, aspergilliosis, occidiodomycosis, cryptococcal meningitis, and histoplasmosis
11/29/2001	US20010046519 Compositions for nasal administration
11/29/2001	US20010046503 Reduction of adhesions using controlled delivery of active oxygen inhibitors
11/29/2001	US20010046489 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
11/29/2001	US20010046486 Stimulation of thymus for vaccination development
11/29/2001	US20010046478 Water soluble lacquers in combination with topical and systemic antimycotics
11/29/2001	US20010046474 Stabilized preparations for use in metered dose inhalers
11/29/2001	EP1143941A3 Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
11/29/2001	DE10025948A1 Wirkstoffkombination Combination of active ingredients
11/29/2001	DE10025946A1 Wirkstoffkombination Combination of active ingredients
11/29/2001	DE10025890A1 Dosierung von transdermalen Arzneimittelsystemen Dose of transdermal drug delivery systems
11/29/2001	DE10025553A1 Zusammensetzung, enthaltend mindestens ein Aryloxim und mindestens einen Wirkstoff zur Behandlung von Akne und ihre Verwendung Composition containing at least one aryl oxime, and at least one active substance for the treatment of acne and their use
11/29/2001	DE10025308A1 Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln Combination of cerivastatin with ACE inhibitors and their use in medicaments
11/29/2001	DE10024939A1 Neue Diphenylmethanderivate für Arzneimittel New diphenylmethane derivatives for pharmaceuticals
11/29/2001	DE10024752A1 Composition for treating prostate diseases, especially inflammation, hyperplasia or cancer, comprises active agent solution containing dimethyl sulfoxide or hyaluronidase as diffusion promoter, applied using catheter
11/29/2001	CA2429199A1 Drug metabolizing enzymes
11/29/2001	CA2413326A1 Use of baculovirus vectors in gene therapy
11/29/2001	CA2410987A1 Inhibition of smad3 to prevent fibrosis and improve wound healing
11/29/2001	CA2410642A1 Modulation of t-cell receptor interactions
11/29/2001	CA2410531A1 Combination therapy for treatment of depression
11/29/2001	CA2410520A1 Mutated eukariotic translation initiation factor 2 alpha kinase 3, eif2ak3, in patients with neonatal insulin-dependent diabetes and multiple epiphyseal dysplasia (wolcott-rallison syndrome)
11/29/2001	CA2410401A1 A novel treatment for cough
11/29/2001	CA2410293A1 Three-layer parenteral preparations
11/29/2001	CA2410101A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
11/29/2001	CA2410081A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
11/29/2001	CA2409980A1 Conjugates of aminodrugs comprising an oxime bond
11/29/2001	CA2409929A1 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
11/29/2001	CA2409868A1 Modulaton of alpha-6 integrin-mediated responses
11/29/2001	CA2408883A1 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
11/29/2001	CA2408791A1 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
11/29/2001	CA2408777A1 Dosage of transdermal delivery systems
11/29/2001	CA2408749A1 Drug screening systems and assays
11/29/2001	CA2408743A1 Method of detecting inflammatory lung disorders
11/29/2001	CA2408727A1 Benzophenones as inhibitors of il-1.beta. and tnf-.alpha.
11/29/2001	CA2408566A1 Role of ldl receptor protein-1 (lrp-1) in alzheimer's disease
11/29/2001	CA2408562A1 Dehydroascorbic acid formulations and uses thereof
11/29/2001	CA2408387A1 A ligand for enhancing oral and cns delivery of biological agents
11/29/2001	CA2408315A1 Aminoacyl trna synthetases
11/29/2001	CA2408141A1 Neurotransmitter transporters
11/29/2001	CA2408140A1 G-protein coupled receptors
11/29/2001	CA2408036A1 Combination of growth hormone secretagogues and antidepressants
11/29/2001	CA2408033A1 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
11/29/2001	CA2407784A1 Treatment of acute coronary syndrome with glp-1
11/29/2001	CA2407570A1 Compositions and methods for delivery of a molecule into a cell
11/29/2001	CA2407545A1 Crystal structures of p-selectin, p- and e-selectin complexes, and uses thereof
11/28/2001	EP1158050A1 Human cysteinyl leukotriene receptor (CysLT2)
11/28/2001	EP1158004A2 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof
11/28/2001	EP1158002A1 Human G-protein coupled receptor
11/28/2001	EP1157705A2 Use of a phosphodiesterase inhibitor in the manufacture of a medicament for blood pressure stabilization during hemodialysis
11/28/2001	EP1157702A1 Compositions comprising DNA Damaging Agents and p53
11/28/2001	EP1157696A2 Treatment of rumen acidosis with alpha-amylase inhibitors
11/28/2001	EP1157695A1 Method of treating obesity using a neurotensin receptor ligand
11/28/2001	EP1157275A1 Novel transduction molecules and methods for using same
11/28/2001	EP1157104A2 Pyk2 binding proteins
11/28/2001	EP1157043A1 Anti-gpr-9-6 and anti-teck antibodies and methods of identifying modulators of gpr-9-6 and teck functions
11/28/2001	EP1157040A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
11/28/2001	EP1157036A1 Immunomodulating glycopeptide
11/28/2001	EP1156855A1 Composition comprising a tramadol material and a selective cox-2 inhibitor drug
11/28/2001	EP1156853A2 Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h 2? receptor antagonists
11/28/2001	EP1156852A2 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h 2? receptor antagonists
11/28/2001	EP1156828A1 Combination therapy for lymphoproliferative diseases
11/28/2001	EP1156823A1 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
11/28/2001	EP1156820A1 Vascular endothelial growth factor-2
11/28/2001	EP1156818A2 Methods and compositions for regulating protein-protein interactions
11/28/2001	EP1156808A2 Enhancement of return to independent living status with a growth hormone secretagogue
11/28/2001	EP1156803A1 LACTAM INHIBITORS OF FXa AND METHOD
11/28/2001	EP1156797A2 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
11/28/2001	EP1156790A1 Combinations of formoterol and mometasone furoate for asthma
11/28/2001	EP1156789A1 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
11/28/2001	EP1156787A1 Oxadiazole compounds and compositions for delivering active agents
11/28/2001	EP1156765A1 Hemostatic polymer useful for rapid blood coagulation and hemostasis
11/28/2001	EP0853483A4 Novel peptides
11/28/2001	EP0845032B1 Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
11/28/2001	EP0817622B1 Medicament with angiotensin converting enzyme (ace) inhibitors suitable for transdermal application
11/28/2001	CN1324405A Novel G protein-coupled receptor proteins, DNAS thereof and ligands to the same
11/28/2001	CN1324374A Biodegradable low molecular weight triblock polyester polyethylene glocol copolymers having reverse thermal gelation properties
11/28/2001	CN1324251A Method of stimulating prosaposin receptor activity
11/28/2001	CN1324250A Method for treating or preventing viral infections and associated diseases
11/28/2001	CN1324246A Method for enhancing wound healing
11/28/2001	CN1324245A Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents
11/28/2001	CN1324243A Method for treating inflammatory inflammatory diseases using heat shock proteins

1 ... 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 ... 1151